Cutaneous squamous cell carcinoma (cSCC) is one of the most common metastatic skin cancers with increasing incidence. We examined the roles of complement component C3 and complement factor B (CFB) in the growth of cSCC. Analysis of cSCC cell lines (n = 8) and normal human epidermal keratinocytes (n = 11) with real-time quantitative PCR and Western blotting revealed up-regulation of C3 and CFB expression in cSCC cells. Immunohistochemical staining revealed stronger tumor cell–specific labeling for C3 and CFB in invasive cSCCs (n = 71) and recessive dystrophic epidermolysis bullosa–associated cSCCs (n = 11) than in cSCC in situ (n = 69), actinic keratoses (n = 63), and normal skin (n = 5). Significant up-regulation of C3 and CFB mRNA expression was noted in chemically induced mouse cSCCs, compared to benign papillomas. Knockdown of C3 and CFB expression inhibited migration and proliferation of cSCC cells and resulted in potent inhibition of extracellular signal–regulated kinase 1/2 activation. Knockdown of C3 and CFB markedly inhibited growth of human cSCC xenograft tumors in vivo. These results provide evidence for the roles of C3 and CFB in the development of cSCC and identify them as biomarkers and potential therapeutic targets in this metastatic skin cancer.

cell, onset of inflammation, and macrophage or B-cell stimulation.\textsuperscript{6,7} C3a is an anaphylatoxin, and C3b binds covalently to the surface of foreign and host cells. On host cell surface, the C3b fragment is inactivated by different soluble and membrane-bound inhibitors [ie, complement factors H and I, complement receptor 1 (CD35), membrane cofactor protein (CD46), and decay accelerating factor (CD55)].\textsuperscript{5,8} The classic pathway of the complement system is activated by antibody/antigen complexes, and the lectin pathway is activated by specific carbohydrates on microbial surfaces. In the alternative pathway, constant spontaneous breakdown of C3 takes place at low level in plasma, resulting in formation of complex C3b(H2O) (alias iC3). Complement factor B (CFB) is an important soluble component in the alternative pathway.\textsuperscript{8} CFB binds to C3b(H2O) and is cleaved by complement factor D, a serine proteinase, to fragments Ba and Bb. The activated component Bb is a serine proteinase, which remains attached to C3b and forms the alternative pathway convertase, C3bBb. This convertase is a key enzyme in the activation of the alternative pathway, as it cleaves more C3 to C3b, generating an amplification loop for the activation of the alternative pathway.

Previous studies have shown that normal human epidermal keratinocytes (NHEKs) produce C3 and CFB\textsuperscript{9} and that their production is regulated by inflammatory cytokines.\textsuperscript{10} Inhibitors of the complement system are also produced by epidermal keratinocytes.\textsuperscript{11,12} We have previously reported that the expression of two important inhibitors of the alternative pathway, complement factors H and I, is specifically up-regulated in tumor cells in cSCCs.\textsuperscript{13,14} In addition, expression profiling of cSCC cell lines has revealed elevated expression of C3 and CFB mRNAs, as compared to NHEKs.\textsuperscript{13,14}

Herein, we have examined the roles of C3 and CFB in the development of cSCC. The results show specific up-regulation of the expression of C3 and CFB by cSCC cells in culture and by tumor cells in cSCCs \textit{in vivo}. The results also show that C3 and CFB regulate proliferation and migration of cSCC cells and promote growth of cSCC xenografts \textit{in vivo}. These results identify C3 and CFB as tumor cell-associated biomarkers for development of cSCC and suggest them as biomarkers and potential therapeutic targets in recurrent and metastatic cSCCs.

**Materials and Methods**

**Ethical Issues**

Collection of normal skin and cSCC tissues and the use of archival tissue specimens was approved by the Ethics Committee of the Hospital District of Southwest Finland. The study was performed according to the Declaration of Helsinki. All patients gave written and informed permission before surgery, and the study was performed with the authorization of Turku University Hospital (Turku, Finland). The experiments with mice were performed with the permission of the State Provincial Office of Southern Finland, according to institutional guidelines.

**Cell Cultures**

Human cSCC cell lines (n = 8) were established from surgically removed SCCs of skin.\textsuperscript{15,16} Five cSCC cell lines were derived from primary cSCCs (UT-SCC-12A, UT-SCC-91, UT-SCC-105, UT-SCC-111, and UT-SCC-118) and three from metastatic cSCCs (UT-SCC-7, UT-SCC-59A, and UT-SCC-115). Cell lines were authenticated by STR DNA profiling.\textsuperscript{15} The spontaneously immortalized nontumorigenic human keratinocyte—derived cell line HaCaT\textsuperscript{16,17} and three Ha-ras—transformed tumorigenic HaCaT cell lines (A5, II-4, and RT3)\textsuperscript{18} were kindly provided by Dr. Norbert Fusenig (German Cancer Research Center, Heidelberg, Germany). A5 cells form benign, II-4 cells low-grade malignant, and RT3 cells high-grade malignant tumors in nude mice \textit{in vivo}.\textsuperscript{19} NHEKs were cultured from nonmalignant skin of patients (n = 10) undergoing surgery for mammoplasty at Turku University Hospital. In addition, primary human epidermal keratinocytes (NHEK-PC) were acquired from PromoCell (Heidelberg, Germany). Cells were cultured, as previously described.\textsuperscript{13,14} To study the effect of inflammatory cytokines, cultures were maintained in serum-free Dulbecco’s modified Eagle’s medium for 24 hours, and then treated with 100 U/mL interferon (IFN)–γ (Promega, Madison, WI) or 20 ng/mL tumor necrosis factor (TNF)-α (Sigma, St. Louis, MO) for 24 hours.

**Tissue RNA**

Normal human skin samples (n = 10) were obtained from the upper arm of healthy volunteers or during mammoplasty operation in Turku University Hospital. Primary cSCC (n = 6) samples were collected from surgically removed tumors in Turku University Hospital.\textsuperscript{15} Total RNA was isolated from the tissue samples and analyzed by real-time quantitative RT-PCR (RT-qPCR), as previously described.\textsuperscript{20}

**RT-qPCR**

The cell cultures were incubated in serum-free media for 24 hours before RNA isolation. Total RNA extraction was performed by using RNeasy Mini Kit (Qiagen, Chatsworth, CA). cDNA was synthesized using 1 μg of RNA treated with RQ1 DNase (M610A; Promega Corp., Madison, WI), random primers (C118A; Promega), M-MLV Reverse Transcriptase (M531A; Promega), and RNase H minus polymerase (M368B; Promega). The mRNA levels for C3, CFB, and β-actin were determined by RT-qPCR using specific primers and dual-labeled fluorescent probes designed by RealTimeDesign software (Biosearch Technologies, Petaluma, CA) (Table 1).\textsuperscript{20} Murine functional
CFB consists of two isoforms that are coded by different variants, variants 1 and 2. C3 and CFB mRNA levels were corrected for levels of β-actin mRNA. In each measurement, range of the threshold cycle values was <5% of the mean and the samples were analyzed in duplicate.

**Western Blot Analysis**

Production of C3 and CFB by NHEKs, cSCC, and HaCaT cell lines was determined by Western blot analysis of aliquots of total cell lysates or conditioned media under nonreducing conditions using specific polyclonal goat anti-C3 and anti-CFB antibodies (both from Calbiochem, San Diego, CA). Equal protein loading was confirmed with β-actin antibody (A 1978; Sigma-Aldrich, St. Louis, MO).14

**Tissue Samples and Immunohistochemistry**

Altogether, 221 archival formalin-fixed, paraffin-embedded tissue samples from sporadic, UV-induced cSCC (n = 71; mean age, 79 years; range, 45 to 102 years), normal skin (n = 69; mean age, 79 years; range, 45 to 102 years), AK (n = 63; mean age, 78 years; range, 59 to 95 years), AKIS (n = 5; mean age, 79 years; range, 45 to 102 years), or RDEB (n = 11; mean age, 33 years; range, 12 to 56 years) were used.21,22 Human tissue samples were assembled into tissue microarray blocks, as previously described,23 to enhance comparability. One representative cSCC sample was also analyzed as a whole tissue section. The sections were stained with goat polyclonal antibodies for C3 and CFB (both from Calbiochem) diluted in phosphate-buffered saline containing 1.5% horse serum. Immunostaining was performed with avidin–biotin–peroxidase complex technique (Vector stain ABC Kit; Vector Laboratories, Inc., Burlingame, CA) in combination with diaminobenzidine and Mayer’s hematoxylin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) as a counterstain.21 Negative control staining was performed by replacing the primary antibody with phosphate-buffered saline. The immunostainings of C3 and CFB were scored as negative (−), weak (+), moderate (++), or strong (+++), on the basis of the intensity of cell surface and cytoplasmatic staining, by two independent observers (P.R. and M.K.). Whole slides of cSCC samples were digitally scanned using a Pannoramic 250 Slide Scanner (3DHistech, Budapest, Hungary).

**siRNA Knockdown of C3 and CFB Expression**

For siRNA knockdown of C3 and CFB, cSCC cells were grown to 50% confluency and transfected with siRNA targeting C3 (HS_C3_8, 5′-ACGGTGTGTCATATGGTTCTCTA-3′; HS_C3_6, 5′-CAGCGGAAGGCGGATGCACT-3′; HS_C3_7, 5′-TAGGAAACCCCTCATCCTATC-3′; or CFB (HS_CFB_1, 5′-CAGCCGGAGACCAATGTTGCAC-3′; HS_CFB_3, 5′-CCAGATGACCTCCTCCCTGAAA-3′; or with negative control siRNA (75 nmol/L; all from Qiagen, New Delhi, India) using siLentFect Lipid Reagent (Bio-Rad Laboratories, Hercules, CA), as previously described.23 Cells were harvested at 72 hours, and the function

---

**Table 1**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer/probe</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human C3</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Human CFB</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Human ACTB</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Murine C3</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Murine Cfb variant 1</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Murine Cfb variant 2</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td>Murine Actb</td>
<td>Forward primer</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GTTGACAGTGGCTGAGAT-3′</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>5′-GGGACGATGGCTGAGAT-3′</td>
</tr>
</tbody>
</table>

ACTB, β-actin; CFB, complement factor B; RT-qPCR, real-time quantitative RT-PCR.
of C3 and CFB siRNAs was verified by Western blot analysis. β-Actin served as loading control, and Western blot band intensities were quantified by ImageJ software version 1.47v (NIH, Bethesda, MD; http://imagej.nih.gov/ij).24

Cell Proliferation Assays

cSCC cell cultures were transfected with 75 nmol/L C3 siRNA, CFB siRNA, or negative control siRNA. Cells (1.0 × 10^5 cells/well) were seeded onto 96-well plates 24 hours after transfection. The number of viable cells was determined with WST-1 cell proliferation assay (Roche Diagnostics, Mannheim, Germany) at 0, 24, 48, and 72 hours. The experiment was performed with five to eight parallel wells in each time point with cSCC cell lines UT-SCC-12A and UT-SCC-7 for C3 siRNA, and with cSCC cell lines UT-SCC-12A and UT-SCC-91 for CFB siRNA. Activation of extracellular signal-regulated kinase (ERK) 1/2 was analyzed by Western blotting of the cell lysates with specific rabbit antibody for p44/42 mitogen-activated protein kinase (p-ERK1/2; 9102) and phospho-p44/42 mitogen-activated protein kinase (p-ERK1/2; 9101), both from Cell Signaling Technology (Beverly, MA).

Cell Migration Assays

cSCC cell cultures were transfected with 75 nmol/L C3 siRNAs, CFB siRNAs, or control siRNA and incubated in complete growth medium for 24 hours to reach confluence. Cell division was inhibited with 1 mmol/L hydroxyurea (Sigma Aldrich) treatment in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum for 16 hours. A scratch in the cell monolayer was generated with pipette tip and the incubation of cells was continued in Dulbecco’s modified Eagle’s medium with 1% fetal calf serum and 0.5 mmol/L hydroxyurea for 8 and 24 hours. Migration was analyzed with Olympus IX70 inverted microscope (Olympus Optical Co., Tokyo, Japan) The cell-free areas were measured from two to six areas in one well with ImageJ software version 1.47v^24 in three parallel wells with two cSCC cell lines (UT-SCC-105 and UT-SCC-91).

Human cSCC Xenografts

Human cSCC xenografts were established, as described previously.14,25 UT-SCC-7 cell cultures were transfected with C3 siRNA_7 or control siRNA (n = 8 in both groups). Similarly, UT-SCC-91 cell cultures were transfected with CFB siRNA_1 or control siRNA. After 72 hours in C3 siRNA experiment, cSCC cells (5 × 10^6) and in CFB siRNA experiment, cSCC cells (7 × 10^6) in 100 μL of phosphate-buffered saline were injected s.c. in the back of severe combined immunodeficiency (SCID/SCID) female mice (CB17/Prkdc^scid/IcrneoCrl) (n = 7 to 8 for each group) (Charles River Laboratory). The size of tumors was measured twice a week, and tumor volume was calculated with the formula: V = (length × width^2)/2.26 Tumors were harvested after 18 days for histologic analysis and immunohistochemistry, as previously described.14 Proliferating cells were detected with monoclonal human Ki-67 antibody (MIB-1; Dako, Glostrup, Denmark) and Mayer’s hematoxylin was used as counterstain. The relative number of Ki-67-positive cells was determined by counting 400 to 1000 cells from all sections at ×20 magnification using ImageJ software version 1.47v.24

Mouse Skin Chemical Carcinogenesis

Mouse skin carcinogenesis was induced in FVB/N HanHsd mice (maintained at the Laboratory Animal Center, University of Oulu, Oulu, Finland), as previously described.27 Skin tumor formation was induced first by topical administration of a single dose of 7,12-dimethylbenz[a]anthracene (100 μg; DMBA; Sigma-Aldrich) in 100 μL acetone on the shaved dorsal skin and then followed by treatment of skin with 5 μg 12-O-Tetradecanoylphorbol-13-acetate (TPA) in 100 μL acetone once a week for 20 weeks. The appearance of tumors was examined weekly and mice were sacrificed at week 32 or earlier if invasive carcinomas appeared, tumor size exceeded 10 mm, or tumor load was excessive. DMBA-TPA–induced cSCC (n = 27), benign papillomas (n = 17), hyperplastic TPA-treated (n = 6), acetone-treated (n = 2) and untreated normal (n = 8) skin samples were harvested and processed for histologic examination and RNA extraction, as previously described.27 The skin tissue samples were classified as hyperplasia, or well, moderately, or poorly differentiated SCC on the basis of analysis of hematoxylin and eosin–stained sections. Outliers have been deleted during statistical analysis.

Statistical Analysis

The statistical analyses were performed with the IBM SPSS Statistics software version 22.0 (IBM Corp., Armonk, New York, NY) to determine the significance of differences between two sample groups for RT-qPCR, Ki-67–positive staining, and proliferation and migration assays by Mann-Whitney U test or t-test. Comparison of immunohistochemical (IHC) staining intensity was performed with χ^2 test.

Results

Expression of C3 and CFB Is Up-Regulated in cSCC Cells

In our previous studies, marked up-regulation of the expression of C3 and CFB mRNA was noted in cSCC cell lines by microarray–based expression profiling and RNA sequencing–based whole transcriptome expression profiling.13,14 Herein, the mRNA levels of C3 and CFB were measured by RT-qPCR. The mean expression levels of C3 and CFB mRNAs were significantly higher in cSCC cells (n = 8), as compared to NHEKs (n = 11) (Figure 1A). No difference was noted in the expression levels of C3 mRNA
between primary and metastatic cSCC cell lines. However, the expression level of CFB mRNA was higher in primary cSCC cell lines than in metastatic cSCC cell lines (Figure 1A). Using Western blot analysis, C3 (185 kDa) was detected in conditioned media of cSCC cell lines and NHEKs (n = 4), and the production of C3 was higher in five of eight cSCC cell lines than in NHEKs (Figure 1B). CFB (86 kDa) was detected in the conditioned media of most cSCC cell lines and the production of CFB was higher in six of eight cSCC cell lines than in NHEKs (Figure 1B). Elevated levels of C3 and CFB mRNAs were also detected in RNA from cSCC tumor tissue (n = 6), as compared with RNA from normal skin (n = 11) (Figure 1C).

Expression of C3 and CFB by Tumor Cells in cSCCs in Vivo

The expression of C3 and CFB by tumor cells in cSCCs in vivo was further analyzed by IHC using tissue microarrays consisting of a large panel of tissue samples representing different stages of epidermal carcinogenesis [namely, normal skin (n = 5), premalignant precursor lesion, AK (n = 63), carcinoma in situ (cSCCis; n = 69), and cSCC (n = 71)]. For comparison, tissue samples of an aggressive form of cSCC, RDEBSCC (n = 11) were also included. Prominent tumor cell-specific immunostaining for C3 was noted in cSCCs (Figure 2, A and B). The staining for C3 was either cytoplasmic or on cell surface (Figure 2C). In addition, strong staining intensity for C3 was noted in tumor cells in RDEBSCC samples (Figure 2D). The staining for C3 was clearly weaker in cSCCis and AK tissue sections than in cSCC or RDEBSCC samples. In normal skin group, staining of tissue samples for C3 was less prominent than in cSCC or RDEBSCC samples. In normal skin group, staining of tissue samples for C3 was weak or absent (Figure 2, E and F).
negative or moderate (Figure 2, E and I). Expression of C3 was also analyzed in a representative whole tissue section of cSCC by IHC. Herein, more abundant staining for C3 was seen on surface or in the cytoplasm of tumor cells in well-differentiated parts of the cSCC, whereas in the adjacent AK the specific staining was weaker (Supplemental Figure S1).

Cytoplasmic staining for CFB was detected in tumor cells in cSCC tissue samples (Figure 3C) and was classified mainly as moderate or strong (Figure 3, A and B). As for C3, the staining intensity for CFB was stronger in RDEBSCC tissue sections (Figure 3D). In premalignant lesions (AK) and in cSCCIS, staining for CFB was negative or weak in most tissue samples (Figure 3, F and G). Normal skin was negative or stained weakly for CFB (Figure 3E). No correlation was detected between staining for CFB and the degree of inflammation. Tumor cell–specific immunostaining for CFB was also noted ex vivo in tissue sections of the xenograft tumors established with human cSCC cells (Figure 3H).
(UT-SCC-91) in SCID mice (Figure 3H). Semiquantitative analysis revealed strong or moderate staining for CFB in most tissue sections in cSCC and RDEBSCC groups (Figure 3I). In comparison, the proportion of negative (-) and weak (+) staining for CFB was significantly higher in AK and cSCCIS groups than in cSCC or RDEBSCC tissues. In normal skin group, staining of tissue samples for CFB was weak or negative (Figure 3, E and I). Expression of CFB was also analyzed in a whole cSCC tissue section by IHC. Herein, the staining was stronger on surface or in the cytoplasm of tumor cells in well-differentiated parts of the cSCC, whereas in the adjacent tissue representing AK the staining was weak (Supplemental Figure S1).

Expression of C3 and CFB in Chemically Induced Mouse cSCC

To further examine the expression of C3 and CFB during cSCC growth, mouse model of chemically induced cSCC was used.15,27 Total RNA samples from normal skin (n = 8), acetone-treated skin (n = 2), TPA-treated hyperplastic skin (n = 6), papilloma (n = 17), and DMBA-TPA–induced cSCC (n = 25) were analyzed by RT-qPCR for the mRNA levels of C3 and two murine variants of CFB, variants 1 and 2. The results showed that the expression of mRNAs for C3 and CFB variants 1 and 2 was significantly higher in mouse cSCCs than in nonmalignant papilloma tissues (Figure 4).

Figure 4  Expression of C3 and complement factor B (CFB) in chemically induced mouse cutaneous squamous cell carcinoma (cSCC). The mRNA levels for mouse C3, CFB variant 1, and CFB variant 2 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPA–induced cSCC were determined by real-time quantitative RT-PCR and corrected for the levels of β-actin mRNA in the same samples. Horizontal bars in box plots indicate median, boxes indicate interquartile range, and whiskers indicate lowest and highest values within 1.5 times the interquartile range for each group. Outliers have been deleted. A: The mRNA levels for mouse C3 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPA–induced cSCC. The expression of C3 mRNA in mouse cSCC is significantly higher than in benign papilloma. B: The mRNA levels for mouse CFB variant 1 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPA–induced cSCC. The expression of CFB variant 1 mRNA is significantly higher in cSCC than in papilloma. C: The mRNA levels of CFB variant 2 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPA–induced cSCC. The expression of CFB variant 2 mRNA is significantly higher in cSCC than in papilloma. n = 8 (A, normal skin); n = 2 (A–C, acetone-treated skin); n = 6 (A–C, TPA-treated hyperplastic skin); n = 16 (A and C, papilloma); n = 25 (A and B, DMBA-TPA–induced cSCC); n = 7 (B and C, normal skin); n = 17 (B, papilloma); n = 23 (C, DMBA-TPA–induced cSCC). *** P < 0.001.
Expression of C3 and CFB in Tumorigenic Ha-ras-Transformed HaCaT Cells

To further investigate the significance of C3 and CFB in the epidermal carcinogenesis, the expression of C3 and CFB was determined in immortalized nontumorigenic keratinocyte-derived cell line (HaCaT) lacking functional p53, and in three Ha-ras-transformed tumorigenic HaCaT-derived cell lines (A5, II-4, and RT3).19 Production of C3 and CFB was elevated in invasive tumorigenic cell line II-4 and was highest in metastatic cell line RT3 (Figure 5A). As shown previously,13,14 the C3 inhibitors complement factors H and I are expressed by cSCC cells. The function of these inhibitors is seen by the presence of C3 cleavage fragments in the media of RT3 cells (Figure 5A).

Regulation of C3 and CFB Expression in cSCC Cell Lines

To examine the regulation of C3 and CFB expression, cSCC cell line cultures were treated with inflammatory cytokines IFN-γ or TNF-α. In primary cSCC cell line (UT-SCC-105), the mRNA expression of C3 was up-regulated by IFN-γ (Figure 5B). The expression of CFB mRNA was up-regulated by IFN-γ and TNF-α in another primary cSCC cell line (UT-SCC-118) (Figure 5B).

C3 and CFB Regulate cSCC Cell Proliferation and Migration

To examine the functional roles of C3 and CFB in cSCC cells, their expression was silenced by specific siRNAs (Figure 6A and Supplemental Figure S2A). Significant reduction in the number of viable cSCC cells was noted 72 hours after transfection with C3 siRNAs and CFB siRNAs (Figure 6B). The inhibitory effect of C3 and CFB knockdown on cSCC cell proliferation was preceded by inhibition of ERK1/2 activation noted 48 hours after siRNA transfection. Levels of p-ERK1/2 were quantitated by densitometry and corrected for the levels of total ERK1/2 in the same samples. Values are shown below the Western blots relative to the levels in control siRNA-transfected cultures (1.00). cSCC cells (UT-SCC-12A) were transfected with 75 nmol/L control siRNA, C3 siRNA, or CFB siRNA. The number of viable cells was determined at 72 hours using WST-1 assay. cSCC cell (UT-SCC-12A) lysates were analyzed for the levels of phosphorylated extracellular signal-regulated kinase-1/2 (p-ERK1/2) and total ERK1/2 by Western blotting 48 hours after siRNA transfection. Levels of p-ERK1/2 were quantitated by densitometry and corrected for the levels of total ERK1/2 in the same samples. Values are shown below the Western blots relative to the levels in control siRNA-transfected cultures (1.00). cSCC cells (UT-SCC-105) were transfected with 75 nmol/L control siRNA, C3 siRNA, or CFB siRNA and incubated for 24 hours. The cultures were then treated with 1 mmol/L hydroxyurea for 16 hours to inhibit cell proliferation. A scratch was generated in the cell monolayer by pipette tip and incubation was continued in Dulbecco’s modified Eagle’s medium with 1% fetal calf serum and 0.5 mmol/L hydroxyurea for 8 and 24 hours. Quantitation of the relative migration rate for C3 and CFB siRNA transfected cultures. Representative images at time points 0 and 24 hours are shown. Data are expressed as means ± SEM (D). n = 7 to 8 parallel wells (B); n = 3 (D). **P < 0.01, ***P < 0.001 (t-test).
C3 and CFB Regulate cSCC Growth in Vivo

The roles of C3 and CFB on cSCC growth was examined in vivo in a xenograft model. Cultures of metastatic cSCC cells (UT-SCC-7) were transfected with C3 siRNA or control siRNA and incubated for 72 hours. Cells (5 x 10⁶) were injected s.c. in the back of SCID mice and the size of tumors was measured twice a week. t-Test was used. B: The xenograft tumors were harvested after 18 days and histologic analysis performed in tumor sections stained with hematoxylin and eosin (H&E). Proliferating cells in xenografts were detected by immunohistochemistry for Ki-67 with Mayer’s hematoxylin as counterstain. Representative staining from each group are shown. C: The relative number of Ki-67-positive cells was determined by counting 400 to 1000 cells at ×20 magnification in all tumor sections using digital imaging. Horizontal bars indicate the mean values for each group (Mann-Whitney U test). Data are expressed as means ± SEM (A). n = 8 (A and C). *P < 0.05, ***P < 0.001. Scale bar = 200 μm (B).

Figure 7 Knockdown of C3 suppresses growth of cutaneous squamous cell carcinoma (cSCC) in vivo. A: Metastatic cSCC cells (UT-SCC-7) were transfected with C3 siRNA or control siRNA and incubated for 72 hours. Cells (5 x 10⁶) were injected s.c. in the back of SCID mice and the size of tumors was measured twice a week. t-Test was used. B: The xenograft tumors were harvested after 18 days and histologic analysis performed in tumor sections stained with hematoxylin and eosin (H&E). Proliferating cells in xenografts were detected by immunohistochemistry for Ki-67 with Mayer’s hematoxylin as counterstain. Representative staining from each group are shown. C: The relative number of Ki-67-positive cells was determined by counting 400 to 1000 cells at ×20 magnification in all tumor sections using digital imaging. Horizontal bars indicate the mean values for each group (Mann-Whitney U test). Data are expressed as means ± SEM (A). n = 8 (A and C). *P < 0.05, ***P < 0.001. Scale bar = 200 μm (B).
Discussion

The results of this study demonstrate elevated expression of C3 and CFB mRNA in cSCC cells in culture and in vivo compared to NHEKs and normal intact skin, respectively. In addition, increased production of C3 and CFB by cSCC cells in culture was noted (Figure 1). Analysis of tissue microarrays consisting of a large panel of cSCC, cSCCIS, AK, and normal skin by IHC revealed specific cytoplasmic staining for C3 and CFB in tumor cells in cSCC in vivo. In addition, staining for C3 was noted on cSCC cell surface in tumors in vivo (Figure 2). Immunostaining for C3 was moderate or strong in most cSCCs and in an aggressive form of cSCC, RDEBSCC, staining for C3 was mainly strong. No tumors with negative staining for C3 were detected in cSCC or in RDEBSCC groups, whereas in premalignant lesions, actinic keratosis (AK) and in situ tumors (cSCCIS), weak or negative staining was noted. In normal intact skin, staining for C3 was negative in almost half of the cases. Similarly, staining for CFB was stronger in cSCC tumors compared to cSCCISs, AK, and normal skin (Figure 3). In almost all RDEBSCC samples, staining for CFB was strong, and in most cases in cSCC group, staining was strong or moderate. No negative staining for CFB was noted in any cSCC or RDEBSCC tissue sample. Only few samples of AK and cSCCIS stained strongly for CFB, and most stained weakly or were negative. Most normal skin samples were also negative for CFB. In summary, the results of IHC staining suggest C3 and CFB as biomarkers for development of cSCC to the invasive stage.

Additional evidence for the roles of C3 and CFB in cutaneous carcinogenesis was obtained with examination of chemically induced mouse cSCCs. The results showed that the mean expression levels of C3 and CFB mRNAs were...
higher in mouse cSCCs than in papillomas, TPA-treated hyperplastic skin, or normal skin (Figure 4). Together, these observations show that the expression of C3 and CFB is significantly up-regulated in invasive cSCCs in vivo, suggesting roles for them in the growth of cSCC. Our findings are supported by previous observations showing expression of C3 and CFB by tumor cells in rhabdomyosarcoma and glioma and CFB in pancreatic ductal adenocarcinoma. C3 has been suggested as a prognostic factor in different stages of keratinocyte carcinogenesis, the expression of C3 and CFB was associated with the tumorigenic potential (Figure 5A). The basal expression of C3 and CFB was low in parental HaCaT cells and in benign tumorigenic Ha-ras-transformed HaCaT cell line (A5). In contrast, the expression of C3 and CFB was clearly higher in the tumorigenic cell line II-4 and in the most aggressive invasive tumorigenic cell line RT3. These findings reveal that the basal expression of C3 and CFB is not induced by p53 inactivation or ras-transformation alone, but that other mechanisms are obviously required. Our results also show that the level of C3 expression is enhanced by IFN-γ in cSCC cells and that the basal CFB expression is up-regulated by both IFN-γ and TNF-α in cSCC cells (Figure 5B). In previous studies, IFN-γ has been shown to up-regulate C3 and CFB expression and TNF-α to up-regulate C3 expression in keratinocytes. These results show that C3 and CFB expression by cSCC cells is susceptible to regulation by inflammatory cytokines present in the tumor microenvironment of cSCCs.

Silencing of C3 and CFB expression in cSCC cells revealed that both C3 and CFB promote proliferation and migration of cSCC cells (Figure 6). Additional functional in vivo studies using xenograft model of human cSCC in SCID mice showed that knockdown of C3 or CFB resulted in significant delay in cSCC xenograft growth and in reduction in the number of proliferating cells in the tumors (Figures 7 and 8). These observations are in accordance with our finding that knockdown of C3 and CFB potently inhibited activation of ERK1/2 and proliferation of cSCC cells (Figure 6). C3 cleavage product C3a has been shown to activate mitogenic signaling pathways (phosphatidylinositol 3-kinase/AKT), activate cell cycle, and increase production of TNF-α, transforming growth factor-β, and IL-6. In addition, CFB activation fragment Bb is a serine protease and it is therefore possible that CFB may exert additional functions in cSCC growth beyond complement system activation. In summary, these results provide evidence for the roles of C3 and CFB in cSCC growth in vivo.

Recently, the indirect effects of complement system on tumor growth by altering the host immune response have been emphasized. UV radiation and immunosuppression are important risk factors for initiation and development of cSCC. UV radiation has been shown to exert an immunosuppressive effect in skin, and CFB has recently been identified as an important mediator of UVA- and UVB-induced immunosuppression. CFB may serve as a molecular link between UV-induced immunosuppression in skin and development of cSCC. Chronic inflammation is also a risk factor for cSCC, and complement activation has been shown to promote colitis-associated carcinogenesis through activation of IL-1β. Complement activation releases anaphylatoxins C3a and C5a, both of which may modulate tumor microenvironment by serving as chemotaxis and promoting generation of radical oxygen species, by increasing vascular permeability, and by increasing histamine release from mast cells.

In summary, the results of this study show that complement system components C3 and CFB are overexpressed by tumor cells in cSCC in vivo, suggesting that these components play important roles in cSCC growth. In addition, our results show that C3 and CFB regulate proliferation and migration of cSCC cells and promote growth of cSCC xenografts in vivo. These results identify C3 and CFB as tumor cell–associated molecular markers for development of cSCC and suggest them as potential therapeutic targets in recurrent and metastatic cSCCs.

Acknowledgments

We thank Johanna Markola, Sari Pitkänen, and Sinikka Kollanus for technical assistance.

Supplemental Data

Supplemental material for this article can be found at http://dx.doi.org/10.1016/j.ajpath.2017.01.006.

References